Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00969085|
Recruitment Status : Withdrawn
First Posted : August 31, 2009
Last Update Posted : September 7, 2012
|Condition or disease||Intervention/treatment||Phase|
|Cutaneous T-cell Lymphoma||Drug: Curcumin (Turmeric) Behavioral: Questionnaires Other: Photos||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Curcumin in Cutaneous T-cell Lymphoma Patients|
|Study Start Date :||November 2012|
|Estimated Primary Completion Date :||November 2014|
Drug: Curcumin (Turmeric)
Chew then swallow 2 sticks per day for up to 6 months.
2 sticks = 1 packet of curcumin = 8 grams
Other Name: Turmeric
Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
Other Name: Surveys
Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
Other Name: Pictures
- Response Rate using Physician's Global Assessment (PGA) based on Severity-Weighted Assessment Tool (SWAT) [ Time Frame: Assessed every 4 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00969085
|Study Chair:||Madeleine Duvic, MD||UT MD Anderson Cancer Center|